ARS Pharmaceuticals, Inc. Payments to Acquire Short-term Investments
ARS Pharmaceuticals, Inc. (SPRY) reported Payments to Acquire Short-term Investments of $34.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2026-06-30 was $19.91M, a 36.54% decline year-over-year.
- ARS Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2026-03-31 was $14.71M, a 57.17% decline year-over-year.
- ARS Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2025-12-31 was $48.89M, a 70.09% decline year-over-year.
- ARS Pharmaceuticals, Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $127.42M, a 206.74% increase year-over-year.
- ARS Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2025 was $242.03M, a 32.02% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2024 was $356.04M, a 30.89% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2023 was $272.00M.
- ARS Pharmaceuticals, Inc. payments to acquire short-term investments for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month | Payments to Acquire Short-term Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $19.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $34.62M 10-Q · filed 2026-08-13 | $83.51M derived: sum of 3 quarters · filed 2026-08-13 | $210.93M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $14.71M 10-Q · filed 2026-05-15 | $63.59M derived: sum of 2 quarters · filed 2026-05-15 | $191.02M derived: sum of 3 quarters · filed 2026-05-15 | $222.40M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $48.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $176.31M derived: sum of 2 quarters · filed 2026-03-09 | $207.69M derived: sum of 3 quarters · filed 2026-08-13 | $242.03M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $127.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $158.80M derived: sum of 2 quarters · filed 2026-08-13 | $193.15M 10-Q · filed 2025-11-10 | $356.61M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $31.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $65.72M 10-Q · filed 2026-08-13 | $229.18M derived: sum of 3 quarters · filed 2026-08-13 | $270.72M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $34.34M 10-Q · filed 2026-05-15 | $197.80M derived: sum of 2 quarters · filed 2026-05-15 | $239.34M derived: sum of 3 quarters · filed 2026-05-15 | $326.95M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $163.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $205.00M derived: sum of 2 quarters · filed 2026-03-09 | $292.61M derived: sum of 3 quarters · filed 2026-03-09 | $356.04M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $41.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $129.15M derived: sum of 2 quarters · filed 2025-11-10 | $192.58M 10-Q · filed 2025-11-10 | $226.63M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $87.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $151.04M 10-Q · filed 2025-08-13 | $185.09M derived: sum of 3 quarters · filed 2025-08-13 | $291.69M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $63.43M 10-Q · filed 2025-05-14 | $97.48M derived: sum of 2 quarters · filed 2025-05-14 | $204.08M derived: sum of 3 quarters · filed 2025-05-14 | $204.08M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $34.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $140.65M derived: sum of 2 quarters · filed 2025-03-20 | $140.65M derived: sum of 3 quarters · filed 2025-03-20 | $272.00M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $106.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $106.60M derived: sum of 2 quarters · filed 2024-11-13 | $237.95M 10-Q · filed 2024-11-13 | $237.95M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $131.35M 10-Q · filed 2024-08-06 | $131.35M derived: sum of 3 quarters · filed 2024-08-06 | $131.35M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | $131.35M 10-Q · filed 2024-05-09 | $131.35M derived: sum of 2 quarters · filed 2024-05-09 | $131.35M derived: sum of 3 quarters · filed 2024-05-09 | $131.35M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 | $63.47M 10-K · filed 2023-03-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |